174221-32-0Relevant articles and documents
Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)
Broadhurst,Brown,Lawton,Ballantyne,Borkakoti,Bottomley,Cooper,Eatherton,Kilford,Malsher,Nixon,Lewis,Sutton,Johnson
, p. 2299 - 2302 (2007/10/03)
A novel series of MMP inhibitors has been identified. The compounds are potent selective inhibitors of collagenase with good solubility and oral bioavailability. One compound, designated Ro32-3555, has been selected for development as a cartilage protective agent for use in the treatment of rheumatoid- and osteoarthritis.